Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Repurposed FDA-Approved Compounds for the Treatment of SARS-CoV2 / COVID-19

Using in silico protein-ligand structure prediction algorithms developed at the University of Missouri (MU), researchers identified multiple FDA-approved drugs with potential to interfere with four essential SARS-CoV2 viral proteins (nsp13 helicase, PLpro, 3CLpro, and NSP12). Repurposing these FDA-approved drugs provides a unique opportunity to respond quickly to the COVID-19 pandemic.

As of May, 2020, the Coronavirus Disease (COVID‐19) pandemic has, in its first 6 months, claimed ~300,000 lives, and has caused more than 4.18 million infections globally. COVID‐19 results from infection by severe acute respiratory syndrome coronavirus 2 (SARS CoV‐2).

Due to their essential roles, several viral proteins have been identified as attractive drug targets. Among them, nsp13 helicase is essential in viral replication; papain-like protease (PLpro) and 3C-like protease (3CLpro) are cysteine proteases that process the viral polyprotein; and nsp12 RdRp catalyzes the replication of the viral RNA genome.

MU researchers have used their novel protein-ligand structure prediction algorithm and in silico screening methods to identify multiple FDA-approved drugs with therapeutic potential for COVID-19.

- Treatment of SARS-CoV2 / COVID-19

- FDA-approved small molecule inhibitors, potential for expedited approval for COVID-19
- >30 candidate therapeutics targeting four essential viral proteins
State of Development

Additional Details


University of Missouri-Columbia

Intellectual Property Protection

Pending Patent

Interested? Request More Information